ObjectiveTo systematically evaluate the effect of combination of motherwort injection and oxytocin for promoting the involution of uterus. MethodsData of randomized controlled trials (RCTs) of motherwort injection and oxytocin in promoting the effect of postpartum involution of uterus were collected by searching the electronic databases including PubMed, EMbase, CNKI, WanFang Data, CENTRAL and WHO ICTRP from inception to August 26th, 2016. Two reviewers independently screened literatures according to the inclusion and exclusion criteria, extracted data, and assessed the risk of bias of included studies. Meta-analysis was conducted by RevMan 5.3 software. ResultsA total of 18 RCTs involving 6 468 patients were included. The results of meta-analysis showed that:Compared with the oxytocin alone group, the combination group of motherwort injection and oxytocin was higher on promoting the drop height of uterus (MD=1.33, 95%CI 1.03 to 1.63), lower on the height of uterus (MD=-2.12, 95%CI -2.64 to -1.61) and duration of lochia (MD=-7.11, 95%CI -8.84 to -5.38). There was no statistical difference in adverse effect rate between the two groups (OR=0.87, 95%CI 0.64 to 1.19, P=0.38). ConclusionsMotherwort injection combined with oxytocin is superior to oxytocin alone in promoting the drop height of postpartum uterus and shortening the duration of lochia. Because of the low quality of the included studies, more high quality RCTs are needed to prove the above conclusion.
Strengthening the management and evaluation of clinical pathways is one of the most important strategies of "Healthy China 2030" Strategic Plan. Evidence-based assessment and clinical guidelines can provide the best relevant evidence to develop clinical pathways. We planned to analyze the current situation of clinical pathways in China and explore how to apply evidence-based assessment on clinical pathway management. We searched PubMed, EMbase, ISI, CNKI, WanFang Data, VIP and the The Cochrane Library using "critical pathways" and "clinical guidelines" as key words or subject terms. And we conducted a comparison of their published volume, definitions, differences and connections. The management system of clinical pathway in China is fundamentally flawed, it is still a challenge to implement the clinical pathways effectively without scientific methodologies and standardized evidence-based evaluation system. In order to improve the management quality of clinical pathway in China, we should develop clinical pathways based on national situation and innovate the evaluation system to standardize the clinical pathway management according to WHO recommendations of clinical guideline and appraisal.